Boehringer adds recheck option to equine PPID testing program

Boehringer Ingelheim has added a recheck component to its IDPPID testing program, allowing eligible horses newly diagnosed with pituitary pars intermedia dysfunction, or PPID, and started on Prascend to be reassessed during the current spring 2026 testing window. The update, announced May 11, 2026, gives equine veterinarians a structured way to evaluate treatment response using ACTH, insulin, and glucose testing alongside clinical signs. The company says the program has tested more than 65,000 horses since launching in 2013, and the spring window is open through June 9, with a fall window scheduled for Aug. 18 through Oct. 13. (equimanagement.com)

Why it matters: For equine practitioners, the change formalizes something PPID guidance has long emphasized: newly treated horses need follow-up, not just an initial diagnosis. Current expert recommendations call for reassessing clinical signs, with or without endocrine testing, one to three months after starting pergolide, then repeating monitoring every six to 12 months. That matters because PPID is progressive, ACTH can shift with season, and lab values don't always track neatly with clinical improvement, so a recheck program could help support dose decisions, client compliance, and longer-term disease management. (idppid.com)

What to watch: Watch whether veterinarians adopt the recheck option broadly this spring, and whether Boehringer shares additional data on how repeat testing influences treatment adjustments and outcomes. (equimanagement.com)